ChristianaCare’s Gene Editing Institute has launched DECODR, Inc., a new for‑profit company created to expand access to one of the world’s leading software tools to evaluate the effectiveness of ...

Mission Bio, the single-cell multi-omics leader, today released data showing that its Targeted Single-Cell DNA+RNA Assay ...

Functional genomics is central to modern drug discovery, yet high attrition rates persist. In this article, Dr Salman ...

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, ...

Cathie Wood's ARKK ETF features Tesla, AMD, Coinbase, and CRISPR Therapeutics as top holdings. Discover the fund's focus on ...

Live-cell breakthrough: Munich scientists created a method to repeatedly read genetic activity from living cells, enabling long-term study without cell destruction. CRISPR reimagined: Hong Kong ...

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

B cash runway to mid-2029, pivotal SCD & AATD programs, and attractive valuation—review risks and opportunities now.

New CRISPR paradigm: HKUST scientists created a DNA-guided Cas12a system that targets RNA, reversing the traditional RNA-guided DNA targeting model. Clinical potential: The SLEUTH platform ...

Researchers analyzed pancreatic islets from 299 donors and found that differences in alpha, beta, and delta cell composition ...

DNA synthesis technologies, supported by automated synthesizers, high-throughput platforms, oligonucleotide production ...